10x Genomics公布2025年第四季度及全年初步精选业绩 - PR Newswire
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results - PR Newswire
生物技术与制药领域的最新动态
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results - PR Newswire
10X GENOMICS Q4 2025 Earnings Preview: Recent $TXG Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
10x Genomics (TXG) Deepens Transplant Research Ties With CareDx, But What Does It Signal Strategically? - simplywall.st
10X Genomics stock hits 52-week high at 20.36 USD By Investing.com - Investing.com Australia
Assessing 10x Genomics (TXG) Valuation After Recent Share Price Momentum Shift - Yahoo Finance
CareDx and 10x Genomics partner on transplant rejection research By Investing.com - Investing.com Nigeria
A Look At 10x Genomics (TXG) Valuation After The New ImmuneScape Partnership Announcement - simplywall.st
10x Genomics (TXG) Sees Target Price Increase in Latest Analyst Rating | TXG Stock News - GuruFocus
10x Genomics price target raised to $18 from $15 at TD Cowen - TipRanks
Assessing CareDx (CDNA) Valuation After ImmuneScape Multiomics Collaboration With 10x Genomics - simplywall.st
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response - BioSpace
Assessing CareDx (CDNA) Valuation After ImmuneScape Multiomics Collaboration With 10x Genomics - Sahm
CareDx, 10x Genomics Establish Multiomics Research Initiative - Contract Pharma
CareDx and 10x Genomics partner on transplant rejection research - Investing.com
CareDx, Inc. and 10x Genomics to Launch ImmuneScape - A Multiomics Research Platform to Decode Transplant Rejection and Drug Response - marketscreener.com
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response - Chartmill
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response - Yahoo Finance
10x Genomics Stock (+10%): Analyst Upgrades Spark a Short Cover Rally - Trefis
Why 10x Genomics Stock Is Quietly Climbing - TipRanks
Citi Maintains 10x Genomics(TXG.US) With Hold Rating - 富途牛牛